Ann: New PD1-Vaxx Phase 2 CRC Cancer Trial to Open in UK and AUS, page-46

Agreed.

With its recent records of steady progression of trials, working closely with fda, patents for IP protection, opportunistic acquisitions, synergy, and hust professional scientific R n D activities under experienced leadership with track records, I'd be very surprised if a BP does not seriously considering acquiring it as a fully owned subsidiary arm.

Whether it fits into any of the BP's current agenda and schedule is another matter. But with some of the BPs key products coming to an end in the not too far future, our odds are improving by the day.

Not that the analogy is needed, this reminds me a bit of a resource company's response to its mine lives coming to an end. Acquisitions or mergers or JVs. But even better in IMU's case, there are other options such as licencing or sales of individual products on their own.

Imho.